Abstract 76P
Background
The study is aimed to identify perception and satisfaction of cancer patients who participate in clinical trials.
Methods
The participants of the study were 110 cancer patients who participated in clinical trials over 2nd cycle at a tertiary hospital, Seoul, South Korea. The instruments used were the perception and satisfaction of cancer patients in clinical trials developed after evaluating content validity index. The collected data were analyzed with descriptive statistics, independent t-test, one-way ANOVA and Pearson Correlation Coefficients.
Results
The mean perception of clinical trial of patients was 3.97±0.46 out of 5.0. The mean satisfaction of clinical trial of patients was 4.10±0.55 out of 5.0. The perception of cancer patients in clinical trials was significantly difference according to types of cancers (F = 2.88, p=.018), participation period (F = 3.13, p=.029) and subjective understanding of the clinical trial (t = 2.65, p=.015). Satisfaction of cancer patients showed significant difference according to religion (t = 2.32, p=.023), participation period (F = 3.39, p=.021), motive to participate (F = 3.18, p=.010) and decision maker of participation (t = 2.60, p =.025). Perception and satisfaction of cancer patients in clinical trials were positively correlated (r=.66, p<.001).
Conclusions
The results of study can be used as a basis for education program for cancer patients participating in clinical trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
221P - Comparative analysis of first-line immune checkpoint inhibitor versus carboplatin-based chemotherapy for cisplatin-ineligible metastatic urothelial carcinoma: A multicenter, retrospective real-world evidence
Presenter: Hsiang‐Lan Lai
Session: Poster display session
Resources:
Abstract
222P - Does tumor grade really improve the prognostic ability of the staging system for men with penile cancer: A SEER database analysis
Presenter: Ravi Kanodia
Session: Poster display session
Resources:
Abstract
223TiP - EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma
Presenter: Daniel Petrylak
Session: Poster display session
Resources:
Abstract
230P - Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort
Presenter: Lingying Wu
Session: Poster display session
Resources:
Abstract
231P - Cost-effectiveness of olaparib vs routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore
Presenter: David SP Tan
Session: Poster display session
Resources:
Abstract
233P - Incorporation of correlative studies in ovarian cancers in the era of precision medicine: Assessment of accountability and utility
Presenter: Nadia Hitchen
Session: Poster display session
Resources:
Abstract
234P - Implementation of mainstream BRCA testing in epithelial ovarian cancer in a tertiary centre
Presenter: Edbert Wong
Session: Poster display session
Resources:
Abstract
235P - The efficacy of radiation therapy in ovarian carcinoma: A propensity score analysis of a population-based study
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
236P - Front-line maintenance therapy for platinum-sensitive ovarian cancer: What’s next PARP inhibitors?
Presenter: Han Gong
Session: Poster display session
Resources:
Abstract
237P - PARP inhibitor in platinum resistant ovarian cancer: Single center real world experience
Presenter: Saphalta Baghmar
Session: Poster display session
Resources:
Abstract